View Future GrowthPhoenixBio 과거 순이익 실적과거 기준 점검 3/6PhoenixBio의 수입은 연평균 -10.1%의 비율로 감소해 온 반면, Life Sciences 산업은 수입이 연평균 8.6% 감소했습니다. 매출은 연평균 3%의 비율로 증가해 왔습니다. PhoenixBio의 자기자본이익률은 8.1%이고 순이익률은 8%입니다.핵심 정보-10.15%순이익 성장률-5.94%주당순이익(EPS) 성장률Life Sciences 산업 성장률32.01%매출 성장률2.97%자기자본이익률8.05%순이익률7.99%다음 순이익 업데이트14 Aug 2026최근 과거 실적 업데이트공고 • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2027 Results on Aug 14, 2026PhoenixBio Co., Ltd. announced that they will report Q1, 2027 results on Aug 14, 2026Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥30.75 (vs JP¥111 loss in FY 2025)Full year 2026 results: EPS: JP¥30.75 (up from JP¥111 loss in FY 2025). Revenue: JP¥1.57b (up 1.6% from FY 2025). Net income: JP¥125.0m (up JP¥573.0m from FY 2025). Profit margin: 8.0% (up from net loss in FY 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.공고 • May 10PhoenixBio Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026PhoenixBio Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: JP¥19.90 (vs JP¥6.28 loss in 3Q 2025)Third quarter 2026 results: EPS: JP¥19.90 (up from JP¥6.28 loss in 3Q 2025). Revenue: JP¥444.0m (up 25% from 3Q 2025). Net income: JP¥81.0m (up JP¥107.0m from 3Q 2025). Profit margin: 18% (up from net loss in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.공고 • Dec 02PhoenixBio Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026PhoenixBio Co., Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026Reported Earnings • Nov 19Second quarter 2026 earnings released: JP¥1.72 loss per share (vs JP¥36.30 loss in 2Q 2025)Second quarter 2026 results: JP¥1.72 loss per share (improved from JP¥36.30 loss in 2Q 2025). Revenue: JP¥356.0m (up 5.0% from 2Q 2025). Net loss: JP¥7.00m (loss narrowed 95% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance.모든 업데이트 보기Recent updatesNew Risk • Jun 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.59b (US$9.95m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.공고 • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2027 Results on Aug 14, 2026PhoenixBio Co., Ltd. announced that they will report Q1, 2027 results on Aug 14, 2026Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥30.75 (vs JP¥111 loss in FY 2025)Full year 2026 results: EPS: JP¥30.75 (up from JP¥111 loss in FY 2025). Revenue: JP¥1.57b (up 1.6% from FY 2025). Net income: JP¥125.0m (up JP¥573.0m from FY 2025). Profit margin: 8.0% (up from net loss in FY 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.공고 • May 15PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2026PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2026.공고 • May 10PhoenixBio Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026PhoenixBio Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: JP¥19.90 (vs JP¥6.28 loss in 3Q 2025)Third quarter 2026 results: EPS: JP¥19.90 (up from JP¥6.28 loss in 3Q 2025). Revenue: JP¥444.0m (up 25% from 3Q 2025). Net income: JP¥81.0m (up JP¥107.0m from 3Q 2025). Profit margin: 18% (up from net loss in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.공고 • Dec 02PhoenixBio Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026PhoenixBio Co., Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026분석 기사 • Dec 01Is PhoenixBio (TSE:6190) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Nov 19Second quarter 2026 earnings released: JP¥1.72 loss per share (vs JP¥36.30 loss in 2Q 2025)Second quarter 2026 results: JP¥1.72 loss per share (improved from JP¥36.30 loss in 2Q 2025). Revenue: JP¥356.0m (up 5.0% from 2Q 2025). Net loss: JP¥7.00m (loss narrowed 95% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance.New Risk • Oct 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risk Market cap is less than US$100m (JP¥1.98b market cap, or US$13.0m).공고 • Sep 02PhoenixBio Co., Ltd. to Report Q2, 2026 Results on Nov 14, 2025PhoenixBio Co., Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025Reported Earnings • Aug 16First quarter 2026 earnings released: EPS: JP¥4.69 (vs JP¥5.71 in 1Q 2025)First quarter 2026 results: EPS: JP¥4.69 (down from JP¥5.71 in 1Q 2025). Revenue: JP¥400.0m (down 11% from 1Q 2025). Net income: JP¥19.0m (down 17% from 1Q 2025). Profit margin: 4.8% (down from 5.1% in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.분석 기사 • Aug 05Is PhoenixBio (TSE:6190) A Risky Investment?TSE:6190 1 Year Share Price vs Fair Value Explore PhoenixBio's Fair Values from the Community and select yours Some say...공고 • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2026 Results on Aug 14, 2025PhoenixBio Co., Ltd. announced that they will report Q1, 2026 results on Aug 14, 2025Reported Earnings • May 21Full year 2025 earnings released: JP¥110 loss per share (vs JP¥6.88 profit in FY 2024)Full year 2025 results: JP¥110 loss per share (down from JP¥6.88 profit in FY 2024). Revenue: JP¥1.54b (down 10% from FY 2024). Net loss: JP¥445.0m (down JP¥471.0m from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.공고 • May 15PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2025PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2025.분석 기사 • Apr 07PhoenixBio Co., Ltd. (TSE:6190) Looks Inexpensive After Falling 33% But Perhaps Not Attractive EnoughPhoenixBio Co., Ltd. ( TSE:6190 ) shareholders won't be pleased to see that the share price has had a very rough month...New Risk • Mar 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.49b (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (JP¥1.49b market cap, or US$9.98m).공고 • Mar 04PhoenixBio Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025PhoenixBio Co., Ltd. announced that they will report fiscal year 2025 results on May 15, 2025분석 기사 • Feb 19PhoenixBio Co., Ltd.'s (TSE:6190) Shares Bounce 31% But Its Business Still Trails The IndustryPhoenixBio Co., Ltd. ( TSE:6190 ) shareholders would be excited to see that the share price has had a great month...Reported Earnings • Feb 16Third quarter 2025 earnings released: JP¥6.28 loss per share (vs JP¥3.45 loss in 3Q 2024)Third quarter 2025 results: JP¥6.28 loss per share (further deteriorated from JP¥3.45 loss in 3Q 2024). Revenue: JP¥355.0m (down 21% from 3Q 2024). Net loss: JP¥26.0m (loss widened 100% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (JP¥1.42b market cap, or US$9.31m). Minor Risk Share price has been volatile over the past 3 months (5.1% average weekly change).공고 • Dec 03PhoenixBio Co., Ltd. to Report Q3, 2025 Results on Feb 14, 2025PhoenixBio Co., Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025분석 기사 • Nov 18PhoenixBio Co., Ltd.'s (TSE:6190) Share Price Is Matching Sentiment Around Its RevenuesWith a price-to-sales (or "P/S") ratio of 0.8x PhoenixBio Co., Ltd. ( TSE:6190 ) may be sending bullish signals at the...New Risk • Nov 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.46b (US$9.39m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (JP¥1.46b market cap, or US$9.39m). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.4% net profit margin). Shareholders have been diluted in the past year (8.1% increase in shares outstanding).공고 • Sep 03PhoenixBio Co., Ltd. to Report Q2, 2025 Results on Nov 14, 2024PhoenixBio Co., Ltd. announced that they will report Q2, 2025 results on Nov 14, 2024Reported Earnings • Aug 18First quarter 2025 earnings released: EPS: JP¥5.71 (vs JP¥11.56 in 1Q 2024)First quarter 2025 results: EPS: JP¥5.71 (down from JP¥11.56 in 1Q 2024). Revenue: JP¥449.0m (up 2.3% from 1Q 2024). Net income: JP¥23.0m (down 45% from 1Q 2024). Profit margin: 5.1% (down from 9.6% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to JP¥467, the stock trades at a trailing P/E ratio of 72.9x. Average trailing P/E is 22x in the Life Sciences industry in Japan. Total loss to shareholders of 23% over the past three years.공고 • Jun 06PhoenixBio Co., Ltd. to Report Q1, 2025 Results on Aug 13, 2024PhoenixBio Co., Ltd. announced that they will report Q1, 2025 results on Aug 13, 2024Reported Earnings • May 21Full year 2024 earnings released: EPS: JP¥6.88 (vs JP¥145 in FY 2023)Full year 2024 results: EPS: JP¥6.88 (down from JP¥145 in FY 2023). Revenue: JP¥1.72b (down 19% from FY 2023). Net income: JP¥26.0m (down 95% from FY 2023). Profit margin: 1.5% (down from 23% in FY 2023). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.공고 • May 17PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2024PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2024.공고 • Mar 03PhoenixBio Co., Ltd. to Report Fiscal Year 2024 Results on May 15, 2024PhoenixBio Co., Ltd. announced that they will report fiscal year 2024 results on May 15, 2024Reported Earnings • Feb 17Third quarter 2024 earnings released: JP¥3.45 loss per share (vs JP¥10.86 profit in 3Q 2023)Third quarter 2024 results: JP¥3.45 loss per share (down from JP¥10.86 profit in 3Q 2023). Revenue: JP¥447.0m (down 15% from 3Q 2023). Net loss: JP¥13.0m (down 135% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (JP¥1.92b market cap, or US$12.8m).공고 • Dec 07PhoenixBio Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024PhoenixBio Co., Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024Reported Earnings • Nov 19Second quarter 2024 earnings released: JP¥4.05 loss per share (vs JP¥76.11 profit in 2Q 2023)Second quarter 2024 results: JP¥4.05 loss per share (down from JP¥76.11 profit in 2Q 2023). Revenue: JP¥442.0m (down 36% from 2Q 2023). Net loss: JP¥15.0m (down 106% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.공고 • Sep 06PhoenixBio Co., Ltd. to Report Q2, 2024 Results on Nov 14, 2023PhoenixBio Co., Ltd. announced that they will report Q2, 2024 results on Nov 14, 2023Reported Earnings • Aug 17First quarter 2024 earnings released: EPS: JP¥11.56 (vs JP¥31.15 in 1Q 2023)First quarter 2024 results: EPS: JP¥11.56 (down from JP¥31.15 in 1Q 2023). Revenue: JP¥439.0m (down 1.3% from 1Q 2023). Net income: JP¥42.0m (down 59% from 1Q 2023). Profit margin: 9.6% (down from 23% in 1Q 2023). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.공고 • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2023 Results on Aug 14, 2023PhoenixBio Co., Ltd. announced that they will report Q1, 2023 results on Aug 14, 2023Reported Earnings • May 19Full year 2023 earnings released: EPS: JP¥145 (vs JP¥117 loss in FY 2022)Full year 2023 results: EPS: JP¥145 (up from JP¥117 loss in FY 2022). Revenue: JP¥2.12b (up 60% from FY 2022). Net income: JP¥493.0m (up JP¥880.0m from FY 2022). Profit margin: 23% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 16Third quarter 2023 earnings released: EPS: JP¥10.86 (vs JP¥9.37 loss in 3Q 2022)Third quarter 2023 results: EPS: JP¥10.86 (up from JP¥9.37 loss in 3Q 2022). Revenue: JP¥525.0m (up 77% from 3Q 2022). Net income: JP¥37.0m (up JP¥68.0m from 3Q 2022). Profit margin: 7.0% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.공고 • Dec 04PhoenixBio Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023PhoenixBio Co., Ltd. announced that they will report Q3, 2023 results on Feb 14, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥76.11 (vs JP¥58.69 loss in 2Q 2022)Second quarter 2023 results: EPS: JP¥76.11 (up from JP¥58.69 loss in 2Q 2022). Revenue: JP¥690.0m (up 273% from 2Q 2022). Net income: JP¥253.0m (up JP¥447.0m from 2Q 2022). Profit margin: 37% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 2 highly experienced directors. 1 independent director (6 non-independent directors). Independent Outside Director Yoshinori Fujii was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공고 • Sep 03PhoenixBio Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022PhoenixBio Co., Ltd. announced that they will report Q2, 2023 results on Nov 14, 2022Reported Earnings • Aug 14First quarter 2023 earnings released: EPS: JP¥31.15 (vs JP¥19.46 in 1Q 2022)First quarter 2023 results: EPS: JP¥31.15 (up from JP¥19.46 in 1Q 2022). Revenue: JP¥445.0m (down 1.5% from 1Q 2022). Net income: JP¥103.0m (up 61% from 1Q 2022). Profit margin: 23% (up from 14% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.공고 • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022PhoenixBio Co., Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022공고 • May 18PhoenixBio Co., Ltd., Annual General Meeting, Jun 28, 2022PhoenixBio Co., Ltd., Annual General Meeting, Jun 28, 2022.Reported Earnings • May 17Full year 2022 earnings released: JP¥117 loss per share (vs JP¥73.60 loss in FY 2021)Full year 2022 results: JP¥117 loss per share (down from JP¥73.60 loss in FY 2021). Revenue: JP¥1.32b (up 31% from FY 2021). Net loss: JP¥387.0m (loss widened 63% from FY 2021). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent Outside Director Yoshinori Fujii was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Apr 08PhoenixBio Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022PhoenixBio Co., Ltd. announced that they will report fiscal year 2022 results on May 13, 2022Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥9.37 loss per share (up from JP¥24.33 loss in 3Q 2021). Revenue: JP¥296.0m (up 48% from 3Q 2021). Net loss: JP¥31.0m (loss narrowed 61% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 15Second quarter 2022 earnings released: JP¥58.69 loss per share (vs JP¥44.41 loss in 2Q 2021)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: JP¥185.0m (up 33% from 2Q 2021). Net loss: JP¥194.0m (loss widened 33% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Reported Earnings • May 19Full year 2021 earnings released: JP¥73.60 loss per share (vs JP¥142 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: JP¥1.01b (down 23% from FY 2020). Net loss: JP¥238.0m (loss narrowed 43% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year whereas the company’s share price has fallen by 17% per year.공고 • Mar 04PhoenixBio Co., Ltd. to Report Fiscal Year 2021 Results on May 14, 2021PhoenixBio Co., Ltd. announced that they will report fiscal year 2021 results on May 14, 2021Reported Earnings • Feb 14Third quarter 2021 earnings released: JP¥24.33 loss per share (vs JP¥9.54 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: JP¥200.0m (down 36% from 3Q 2020). Net loss: JP¥80.0m (loss widened 186% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Dec 22New 90-day low: JP¥582The company is down 20% from its price of JP¥727 on 23 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 18% over the same period.Is New 90 Day High Low • Dec 03New 90-day low: JP¥616The company is down 9.0% from its price of JP¥679 on 04 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 7.0% over the same period.공고 • Sep 06PhoenixBio Co., Ltd. to Report Q2, 2021 Results on Nov 13, 2020PhoenixBio Co., Ltd. announced that they will report Q2, 2021 results on Nov 13, 2020공고 • Jun 20PhoenixBio Co., Ltd. to Report Q1, 2021 Results on Aug 12, 2020PhoenixBio Co., Ltd. announced that they will report Q1, 2021 results on Aug 12, 2020매출 및 비용 세부 내역PhoenixBio가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TSE:6190 매출, 비용 및 순이익 (JPY Millions)날짜매출순이익일반관리비연구개발비31 Mar 261,56512591519131 Dec 251,598-20589227330 Sep 251,509-31289427330 Jun 251,492-45292727331 Mar 251,541-44897127331 Dec 241,530-1381,05620630 Sep 241,622-1251,04620630 Jun 241,72571,03320631 Mar 241,7152697520631 Dec 231,79211492320530 Sep 231,87016490720530 Jun 232,11843286920531 Mar 232,12449383620531 Dec 222,05116780021930 Sep 221,8229974621930 Jun 221,317-34868621931 Mar 221,324-38766521931 Dec 211,445-5262122130 Sep 211,349-10161422130 Jun 211,303-5362822131 Mar 211,013-23863622131 Dec 20978-57866623830 Sep 201,090-52670423830 Jun 201,184-45872323831 Mar 201,310-41576523831 Dec 191,231-22071734530 Sep 191,323-20277334530 Jun 191,358-21080534531 Mar 191,228-29780934531 Dec 181,087-30385217630 Sep 181,012-30076717630 Jun 18937-29767617631 Mar 18902-27059317631 Dec 17974-16760114030 Sep 17987-6056614030 Jun 171,014-1355414031 Mar 171,22812855214031 Dec 161,31712158414631 Mar 161,217125488146양질의 수익: 6190는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 6190는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 6190는 지난 5년 동안 흑자전환하며 연평균 -10.1%의 수익 성장을 기록했습니다.성장 가속화: 6190는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: 6190는 지난해 흑자전환하여 지난 해 수익 성장률을 Life Sciences 업계(-16.4%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 6190의 자본 수익률(8.1%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/30 16:03종가2026/07/30 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PhoenixBio Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2027 Results on Aug 14, 2026PhoenixBio Co., Ltd. announced that they will report Q1, 2027 results on Aug 14, 2026
Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥30.75 (vs JP¥111 loss in FY 2025)Full year 2026 results: EPS: JP¥30.75 (up from JP¥111 loss in FY 2025). Revenue: JP¥1.57b (up 1.6% from FY 2025). Net income: JP¥125.0m (up JP¥573.0m from FY 2025). Profit margin: 8.0% (up from net loss in FY 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
공고 • May 10PhoenixBio Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026PhoenixBio Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: JP¥19.90 (vs JP¥6.28 loss in 3Q 2025)Third quarter 2026 results: EPS: JP¥19.90 (up from JP¥6.28 loss in 3Q 2025). Revenue: JP¥444.0m (up 25% from 3Q 2025). Net income: JP¥81.0m (up JP¥107.0m from 3Q 2025). Profit margin: 18% (up from net loss in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.
공고 • Dec 02PhoenixBio Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026PhoenixBio Co., Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026
Reported Earnings • Nov 19Second quarter 2026 earnings released: JP¥1.72 loss per share (vs JP¥36.30 loss in 2Q 2025)Second quarter 2026 results: JP¥1.72 loss per share (improved from JP¥36.30 loss in 2Q 2025). Revenue: JP¥356.0m (up 5.0% from 2Q 2025). Net loss: JP¥7.00m (loss narrowed 95% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance.
New Risk • Jun 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.59b (US$9.95m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
공고 • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2027 Results on Aug 14, 2026PhoenixBio Co., Ltd. announced that they will report Q1, 2027 results on Aug 14, 2026
Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥30.75 (vs JP¥111 loss in FY 2025)Full year 2026 results: EPS: JP¥30.75 (up from JP¥111 loss in FY 2025). Revenue: JP¥1.57b (up 1.6% from FY 2025). Net income: JP¥125.0m (up JP¥573.0m from FY 2025). Profit margin: 8.0% (up from net loss in FY 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
공고 • May 15PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2026PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2026.
공고 • May 10PhoenixBio Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026PhoenixBio Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: JP¥19.90 (vs JP¥6.28 loss in 3Q 2025)Third quarter 2026 results: EPS: JP¥19.90 (up from JP¥6.28 loss in 3Q 2025). Revenue: JP¥444.0m (up 25% from 3Q 2025). Net income: JP¥81.0m (up JP¥107.0m from 3Q 2025). Profit margin: 18% (up from net loss in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.
공고 • Dec 02PhoenixBio Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026PhoenixBio Co., Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026
분석 기사 • Dec 01Is PhoenixBio (TSE:6190) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Nov 19Second quarter 2026 earnings released: JP¥1.72 loss per share (vs JP¥36.30 loss in 2Q 2025)Second quarter 2026 results: JP¥1.72 loss per share (improved from JP¥36.30 loss in 2Q 2025). Revenue: JP¥356.0m (up 5.0% from 2Q 2025). Net loss: JP¥7.00m (loss narrowed 95% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance.
New Risk • Oct 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risk Market cap is less than US$100m (JP¥1.98b market cap, or US$13.0m).
공고 • Sep 02PhoenixBio Co., Ltd. to Report Q2, 2026 Results on Nov 14, 2025PhoenixBio Co., Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025
Reported Earnings • Aug 16First quarter 2026 earnings released: EPS: JP¥4.69 (vs JP¥5.71 in 1Q 2025)First quarter 2026 results: EPS: JP¥4.69 (down from JP¥5.71 in 1Q 2025). Revenue: JP¥400.0m (down 11% from 1Q 2025). Net income: JP¥19.0m (down 17% from 1Q 2025). Profit margin: 4.8% (down from 5.1% in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
분석 기사 • Aug 05Is PhoenixBio (TSE:6190) A Risky Investment?TSE:6190 1 Year Share Price vs Fair Value Explore PhoenixBio's Fair Values from the Community and select yours Some say...
공고 • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2026 Results on Aug 14, 2025PhoenixBio Co., Ltd. announced that they will report Q1, 2026 results on Aug 14, 2025
Reported Earnings • May 21Full year 2025 earnings released: JP¥110 loss per share (vs JP¥6.88 profit in FY 2024)Full year 2025 results: JP¥110 loss per share (down from JP¥6.88 profit in FY 2024). Revenue: JP¥1.54b (down 10% from FY 2024). Net loss: JP¥445.0m (down JP¥471.0m from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.
공고 • May 15PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2025PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2025.
분석 기사 • Apr 07PhoenixBio Co., Ltd. (TSE:6190) Looks Inexpensive After Falling 33% But Perhaps Not Attractive EnoughPhoenixBio Co., Ltd. ( TSE:6190 ) shareholders won't be pleased to see that the share price has had a very rough month...
New Risk • Mar 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.49b (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (JP¥1.49b market cap, or US$9.98m).
공고 • Mar 04PhoenixBio Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025PhoenixBio Co., Ltd. announced that they will report fiscal year 2025 results on May 15, 2025
분석 기사 • Feb 19PhoenixBio Co., Ltd.'s (TSE:6190) Shares Bounce 31% But Its Business Still Trails The IndustryPhoenixBio Co., Ltd. ( TSE:6190 ) shareholders would be excited to see that the share price has had a great month...
Reported Earnings • Feb 16Third quarter 2025 earnings released: JP¥6.28 loss per share (vs JP¥3.45 loss in 3Q 2024)Third quarter 2025 results: JP¥6.28 loss per share (further deteriorated from JP¥3.45 loss in 3Q 2024). Revenue: JP¥355.0m (down 21% from 3Q 2024). Net loss: JP¥26.0m (loss widened 100% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (JP¥1.42b market cap, or US$9.31m). Minor Risk Share price has been volatile over the past 3 months (5.1% average weekly change).
공고 • Dec 03PhoenixBio Co., Ltd. to Report Q3, 2025 Results on Feb 14, 2025PhoenixBio Co., Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025
분석 기사 • Nov 18PhoenixBio Co., Ltd.'s (TSE:6190) Share Price Is Matching Sentiment Around Its RevenuesWith a price-to-sales (or "P/S") ratio of 0.8x PhoenixBio Co., Ltd. ( TSE:6190 ) may be sending bullish signals at the...
New Risk • Nov 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.46b (US$9.39m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (JP¥1.46b market cap, or US$9.39m). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.4% net profit margin). Shareholders have been diluted in the past year (8.1% increase in shares outstanding).
공고 • Sep 03PhoenixBio Co., Ltd. to Report Q2, 2025 Results on Nov 14, 2024PhoenixBio Co., Ltd. announced that they will report Q2, 2025 results on Nov 14, 2024
Reported Earnings • Aug 18First quarter 2025 earnings released: EPS: JP¥5.71 (vs JP¥11.56 in 1Q 2024)First quarter 2025 results: EPS: JP¥5.71 (down from JP¥11.56 in 1Q 2024). Revenue: JP¥449.0m (up 2.3% from 1Q 2024). Net income: JP¥23.0m (down 45% from 1Q 2024). Profit margin: 5.1% (down from 9.6% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to JP¥467, the stock trades at a trailing P/E ratio of 72.9x. Average trailing P/E is 22x in the Life Sciences industry in Japan. Total loss to shareholders of 23% over the past three years.
공고 • Jun 06PhoenixBio Co., Ltd. to Report Q1, 2025 Results on Aug 13, 2024PhoenixBio Co., Ltd. announced that they will report Q1, 2025 results on Aug 13, 2024
Reported Earnings • May 21Full year 2024 earnings released: EPS: JP¥6.88 (vs JP¥145 in FY 2023)Full year 2024 results: EPS: JP¥6.88 (down from JP¥145 in FY 2023). Revenue: JP¥1.72b (down 19% from FY 2023). Net income: JP¥26.0m (down 95% from FY 2023). Profit margin: 1.5% (down from 23% in FY 2023). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
공고 • May 17PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2024PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2024.
공고 • Mar 03PhoenixBio Co., Ltd. to Report Fiscal Year 2024 Results on May 15, 2024PhoenixBio Co., Ltd. announced that they will report fiscal year 2024 results on May 15, 2024
Reported Earnings • Feb 17Third quarter 2024 earnings released: JP¥3.45 loss per share (vs JP¥10.86 profit in 3Q 2023)Third quarter 2024 results: JP¥3.45 loss per share (down from JP¥10.86 profit in 3Q 2023). Revenue: JP¥447.0m (down 15% from 3Q 2023). Net loss: JP¥13.0m (down 135% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (JP¥1.92b market cap, or US$12.8m).
공고 • Dec 07PhoenixBio Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024PhoenixBio Co., Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024
Reported Earnings • Nov 19Second quarter 2024 earnings released: JP¥4.05 loss per share (vs JP¥76.11 profit in 2Q 2023)Second quarter 2024 results: JP¥4.05 loss per share (down from JP¥76.11 profit in 2Q 2023). Revenue: JP¥442.0m (down 36% from 2Q 2023). Net loss: JP¥15.0m (down 106% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
공고 • Sep 06PhoenixBio Co., Ltd. to Report Q2, 2024 Results on Nov 14, 2023PhoenixBio Co., Ltd. announced that they will report Q2, 2024 results on Nov 14, 2023
Reported Earnings • Aug 17First quarter 2024 earnings released: EPS: JP¥11.56 (vs JP¥31.15 in 1Q 2023)First quarter 2024 results: EPS: JP¥11.56 (down from JP¥31.15 in 1Q 2023). Revenue: JP¥439.0m (down 1.3% from 1Q 2023). Net income: JP¥42.0m (down 59% from 1Q 2023). Profit margin: 9.6% (down from 23% in 1Q 2023). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
공고 • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2023 Results on Aug 14, 2023PhoenixBio Co., Ltd. announced that they will report Q1, 2023 results on Aug 14, 2023
Reported Earnings • May 19Full year 2023 earnings released: EPS: JP¥145 (vs JP¥117 loss in FY 2022)Full year 2023 results: EPS: JP¥145 (up from JP¥117 loss in FY 2022). Revenue: JP¥2.12b (up 60% from FY 2022). Net income: JP¥493.0m (up JP¥880.0m from FY 2022). Profit margin: 23% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 16Third quarter 2023 earnings released: EPS: JP¥10.86 (vs JP¥9.37 loss in 3Q 2022)Third quarter 2023 results: EPS: JP¥10.86 (up from JP¥9.37 loss in 3Q 2022). Revenue: JP¥525.0m (up 77% from 3Q 2022). Net income: JP¥37.0m (up JP¥68.0m from 3Q 2022). Profit margin: 7.0% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
공고 • Dec 04PhoenixBio Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023PhoenixBio Co., Ltd. announced that they will report Q3, 2023 results on Feb 14, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥76.11 (vs JP¥58.69 loss in 2Q 2022)Second quarter 2023 results: EPS: JP¥76.11 (up from JP¥58.69 loss in 2Q 2022). Revenue: JP¥690.0m (up 273% from 2Q 2022). Net income: JP¥253.0m (up JP¥447.0m from 2Q 2022). Profit margin: 37% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 2 highly experienced directors. 1 independent director (6 non-independent directors). Independent Outside Director Yoshinori Fujii was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공고 • Sep 03PhoenixBio Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022PhoenixBio Co., Ltd. announced that they will report Q2, 2023 results on Nov 14, 2022
Reported Earnings • Aug 14First quarter 2023 earnings released: EPS: JP¥31.15 (vs JP¥19.46 in 1Q 2022)First quarter 2023 results: EPS: JP¥31.15 (up from JP¥19.46 in 1Q 2022). Revenue: JP¥445.0m (down 1.5% from 1Q 2022). Net income: JP¥103.0m (up 61% from 1Q 2022). Profit margin: 23% (up from 14% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
공고 • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022PhoenixBio Co., Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022
공고 • May 18PhoenixBio Co., Ltd., Annual General Meeting, Jun 28, 2022PhoenixBio Co., Ltd., Annual General Meeting, Jun 28, 2022.
Reported Earnings • May 17Full year 2022 earnings released: JP¥117 loss per share (vs JP¥73.60 loss in FY 2021)Full year 2022 results: JP¥117 loss per share (down from JP¥73.60 loss in FY 2021). Revenue: JP¥1.32b (up 31% from FY 2021). Net loss: JP¥387.0m (loss widened 63% from FY 2021). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent Outside Director Yoshinori Fujii was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Apr 08PhoenixBio Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022PhoenixBio Co., Ltd. announced that they will report fiscal year 2022 results on May 13, 2022
Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥9.37 loss per share (up from JP¥24.33 loss in 3Q 2021). Revenue: JP¥296.0m (up 48% from 3Q 2021). Net loss: JP¥31.0m (loss narrowed 61% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 15Second quarter 2022 earnings released: JP¥58.69 loss per share (vs JP¥44.41 loss in 2Q 2021)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: JP¥185.0m (up 33% from 2Q 2021). Net loss: JP¥194.0m (loss widened 33% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Reported Earnings • May 19Full year 2021 earnings released: JP¥73.60 loss per share (vs JP¥142 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: JP¥1.01b (down 23% from FY 2020). Net loss: JP¥238.0m (loss narrowed 43% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year whereas the company’s share price has fallen by 17% per year.
공고 • Mar 04PhoenixBio Co., Ltd. to Report Fiscal Year 2021 Results on May 14, 2021PhoenixBio Co., Ltd. announced that they will report fiscal year 2021 results on May 14, 2021
Reported Earnings • Feb 14Third quarter 2021 earnings released: JP¥24.33 loss per share (vs JP¥9.54 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: JP¥200.0m (down 36% from 3Q 2020). Net loss: JP¥80.0m (loss widened 186% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Dec 22New 90-day low: JP¥582The company is down 20% from its price of JP¥727 on 23 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 18% over the same period.
Is New 90 Day High Low • Dec 03New 90-day low: JP¥616The company is down 9.0% from its price of JP¥679 on 04 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 7.0% over the same period.
공고 • Sep 06PhoenixBio Co., Ltd. to Report Q2, 2021 Results on Nov 13, 2020PhoenixBio Co., Ltd. announced that they will report Q2, 2021 results on Nov 13, 2020
공고 • Jun 20PhoenixBio Co., Ltd. to Report Q1, 2021 Results on Aug 12, 2020PhoenixBio Co., Ltd. announced that they will report Q1, 2021 results on Aug 12, 2020